Entrada Therapeutics, Inc. (TRDA) Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Entrada Therapeutics, Inc. NASDAQ:TRDA Healthcare · Biotechnology
Mkt Cap $176.58M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Entrada Therapeutics appointed Linea Aspesi as Chief People Officer, an organizational leadership hire rather than a change to the C-suite's scientific or financial leadership.
Ms. Aspesi brings more than twenty years of human resources experience, including Chief People Officer at KalVista Pharmaceuticals and executive HR roles at Editas Medicine, Forma Therapeutics, Saniona, Sobi, and Genzyme.
The appointment comes as Entrada advances clinical-stage neuromuscular programs, including exon 44, 45, 50 and 51 skipping amenable Duchenne muscular dystrophy oligonucleotide programs and the partnered VX-670 program for myotonic dystrophy type 1.
• 11d ago AI analysis › Press Release ⚠ 3
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Entrada Therapeutics reported positive Cohort 1 topline data from the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 in Duchenne patients amenable to exon 45 skipping.
The 5 mg/kg dose met primary safety and tolerability objectives, with a 0.10% mean increase in dystrophin production (n=6, nominal p=0.03) and 0.15% increase in exon skipping versus baseline; all participants rolled into the open-label Phase 2 portion.
Cohort 2 (10 mg/kg) enrollment is complete, with data expected in the first half of 2027, and the company expects meaningfully higher dystrophin production at escalated doses up to 15 mg/kg.
ENTR-601-45's once-every-six-weeks dosing targets roughly nine administrations per year versus more than fifty for weekly infusion regimens, addressing a subpopulation representing about 9% of DMD patients globally.
• 18d ago AI analysis › Press Release
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Entrada Therapeutics announced that an independent Data Monitoring Committee recommended initiating Cohort 3 of the ELEVATE-44-201 Phase 1/2 study at the top dose of 18 mg/kg, up from 12 mg/kg in Cohort 2.
The DMC reviewed safety and PK data from eight participants in the double-blind, placebo-controlled multiple-ascending-dose portion of the study of ENTR-601-44, an exon 44-skipping candidate for Duchenne muscular dystrophy.
The company expects Cohort 1 open-label data by year-end 2026 and Cohort 2 data in Q1 2027; dosing at 18 mg/kg could drive higher exposure, dystrophin production and functional benefit.
• 18d ago AI analysis › Press Release
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Entrada Therapeutics named Parent Project Muscular Dystrophy (U.S.) and Duchenne Parent Project Netherlands as recipients of its fourth annual DREAMS Grant Program, which awards two $50,000 grants to non-profits serving underrepresented parts of the Duchenne muscular dystrophy community.
An independent review committee of neuromuscular specialists, patient advocates and health equity advocates selected the recipients, whose projects focus on expanding equitable access to specialized Duchenne care for adults, rural and underserved populations.
CEO Dipal Doshi tied the awards to this year's World Duchenne Awareness Day theme of 'access changes lives,' positioning the grants as models for improving Duchenne care delivery across borders.
The release is community-relations news aligned with Entrada's Duchenne-focused pipeline (including lead exon-skipping programs and partnered VX-670) and carries no direct financial or clinical impact on the company.
• 1mo ago AI analysis › Press Release
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics granted 61,365 restricted stock units and options to purchase 19,425 shares to eight newly hired non-executive employees, effective September 1, 2026.
The awards were made under the company's 2025 Inducement Equity Plan as a material inducement to employment, per Nasdaq Listing Rule 5635(c)(4), with options priced at $7.07 — the August 31, 2026 closing price.
Vesting follows a standard four-year schedule with a one-year cliff. This is routine equity-compensation boilerplate with no bearing on the company's clinical programs or financial position.
• 1mo ago AI analysis › Press Release ⚠ 2
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Entrada Therapeutics reported Q2 2026 financial results with cash, cash equivalents, and marketable securities of $223.0 million, which management believes is sufficient to fund operations into the third quarter of 2027.
Collaboration revenue for the quarter decreased to $0.9 million from $2.0 million in the prior year, while the net loss narrowed slightly to $42.8 million driven by lower personnel and facility costs.
On the clinical front, the company completed enrollment for Cohort 2 of the ELEVATE-44-201 study and Cohort 1 of the ELEVATE-45-201 study, with data readouts anticipated between October 2026 and the first half of 2027.
• 2mo ago AI analysis › Press Release
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Entrada Therapeutics announced that the independent Data Monitoring Committee for its ELEVATE-45-201 study has recommended escalating the dose for Cohort 2 to 10 mg/kg.
This decision follows a review of safety and pharmacokinetic data from eight participants in Cohort 1, who were treated at 5 mg/kg.
The company expects to report full Cohort 1 data, including early dystrophin expression results, in mid-2026.
• 4mo ago AI analysis › Press Release
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics granted 18,600 restricted stock units to three newly hired non-executive employees.
The grants were made under the company’s 2025 Inducement Equity Plan and approved by the Compensation Committee as a material inducement for employment.
The RSUs vest over four years, with 25% vesting after one year and the remainder quarterly thereafter, subject to continuous service.
• 5mo ago AI analysis › Press Release ● Major
Entrada Therapeutics Reports First Quarter 2026 Financial Results
Entrada Therapeutics reported positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 in DMD, showing statistically significant improvement in Time to Rise velocity and a favorable safety profile.
The company confirmed cash runway into Q3 2027 with $254.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
Financial results for Q1 2026 showed revenue of $0.9 million and a net loss of $39.7 million, with R&D expenses increasing to $33.1 million due to DMD program costs.
• 5mo ago AI analysis › Press Release ● Major ⚠ 2
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
Entrada Therapeutics reported positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 in pediatric Duchenne patients, showing a favorable safety profile and statistically significant improvement in Time to Rise velocity.
Treated participants showed a 2.36% increase in dystrophin over a 4.00% baseline, though plasma exposure was lower than expected compared to healthy adults.
The company has initiated dosing in Cohort 2 at a higher dose of 12 mg/kg and expects to report data by year-end 2026, with modeling predicting higher dystrophin levels.
• 5mo ago AI analysis › Press Release
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Entrada Therapeutics scheduled the release of topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 for May 7, 2026.
The double-blind, placebo-controlled study targets participants with Duchenne Muscular Dystrophy who are exon 44 skipping amenable.
Management will host an investor webcast and conference call at 8:30 a.m. ET on May 7 to discuss the data.
• 5mo ago AI analysis › 
